HALO
T2Halozyme Therapeutics, Inc.
OverviewHalozyme Therapeutics is a biopharmaceutical company specializing in drug delivery. Its ENHANZE platform enables easier subcutaneous administration of medicines
Halozyme Therapeutics is a biopharmaceutical company specializing in drug delivery. Its ENHANZE platform enables easier subcutaneous administration of medicines, generating significant royalty revenue from major partners like J&J, Roche, and argenx. Newer Hypercon and Surf Bio technologies expand its offerings, aiming for a "one-stop shop" for injectable biologics. Royalty revenue is the primary driver, with strong growth from commercialized products and a robust pipeline.
- What They Do (Plain English & Analogies)
- Halozyme Therapeutics is a biopharmaceutical company that specializes in making injectable medicines easier and faster to deliver. Imagine if a large, slow-moving package, like a medicine that typically requires a long IV drip in a hospital, could be shrunk down and delivered quickly to your doorstep (under your skin) in a small, convenient envelope (a subcutaneous injection). Halozyme's core technology, ENHANZE, uses a special enzyme to temporarily open up spaces under the skin, allowing large volumes of medicine to be injected quickly and easily, often in a small shot at home or in a doctor's office. This transforms lengthy IV infusions into quick subcutaneous injections, significantly improving convenience for patients and healthcare providers. The company also has newer technologies, Hypercon and Surf Bio, which further concentrate medicines into even smaller volumes, making them suitable for tiny auto-injectors, similar to an EpiPen, for at-home use. Essentially, Halozyme provides the advanced 'delivery system' for other pharmaceutical companies' drugs.
- Very Brief History
- Founded in 1998, Halozyme Therapeutics initially focused on its proprietary recombinant human hyaluronidase enzyme (rHuPH20), which became the foundation for its ENHANZE drug delivery technology. Over the years, the company built a strong portfolio through strategic partnerships with major pharmaceutical companies. In 2025, Halozyme significantly expanded its drug delivery capabilities by acquiring Elektrofi's Hypercon technology and Surf Bio's hyperconcentration technology, extending its intellectual property into the mid-2040s.
- "Street Stereotype"
- Halozyme is generally perceived by investors and analysts as a "biopharma technology platform company" or a "royalty play." The market primarily focuses on its high-margin, durable royalty streams generated from its ENHANZE technology, which is licensed to major pharmaceutical companies. There is also increasing attention on the potential of its newer drug delivery platforms, Hypercon and Surf Bio, to extend these royalty streams and diversify its revenue base.
- Subsidiaries On Linked In*
- {"subsidiaries":[]}
- Customer Sectors & Example Clients
- Halozyme's customers operate in the Pharmaceuticals, Biotechnology, Oncology, Immunology, Neurology, Inflammatory Bowel Disease, and Obesity sectors. Specific top clients and partners include Johnson & Johnson (for DARZALEX SC, RYBREVANT SC), Roche (for PHESGO, OCREVUS ZUNOVO, TECENTRIQ SC), argenx (for VYVGART Hytrulo), Bristol-Myers Squibb (BMS) (for OPDIVO Qvantig), Viatris (for small volume auto-injector), Pfizer, Eli Lilly, Takeda, Chugai Pharmaceutical, Alexion Pharma Holding, Horizon Therapeutics plc, GSK, Vertex Pharmaceuticals, and Oruka.
- New Customers / Segments They'Re Targeting
- Halozyme is actively targeting new collaborations and expanding the application of its technologies into emerging and high-growth areas. This includes antibody drug conjugates (ADCs) and nucleic acids, where ENHANZE is believed to improve the benefit-risk profile and enable subcutaneous administration. They are also expanding their ENHANZE collaborations into obesity and inflammatory bowel disease. With Hypercon, they are addressing the demand for lower volume, auto-injector-ready therapies for at-home or in-office use, particularly in areas like inflammation, immunology, nephrology, and cardiovascular diseases, where patient self-administration is highly desired.
- Supply Chain And Sourcing Geographies
- Halozyme is investing in manufacturing capacity to offer end-to-end services for its Hypercon partners, ranging from drug substance manufacturing to commercial fill and finish. For Hypercon, they are collaborating with Thermo Fisher Patheon, a Contract Development and Manufacturing Organization (CDMO), for engineering and clinical batches. While specific geographies for these manufacturing operations are not detailed, Halozyme's general operations span the United States, Switzerland, Ireland, Belgium, Japan, and other international markets.
- Sales Geographies And Expansion Plans
- Halozyme's partners sell ENHANZE-enabled products globally. Examples of global sales mentioned include DARZALEX, VYVGART, and PHESGO. OCREVUS ZUNOVO is administered to approximately 24,000 patients globally. The company itself has operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. Halozyme's strategy focuses on expanding the reach of its technologies through new collaboration and licensing agreements with pharmaceutical companies worldwide, rather than directly expanding its own sales force into new geographies.
- How Key Themes May Help/Hurt
- The 'GLP-1 Long '24: Peptide Producers/Designers' theme is largely beneficial for Halozyme. The rising global prevalence of obesity is significantly increasing the demand for GLP-1 drugs. Halozyme's expansion of ENHANZE collaborations into obesity and its development of Hypercon and Surf Bio technologies, which enable lower-volume, auto-injector-ready at-home therapies, position it well to capitalize on this trend. These technologies can make GLP-1 drug administration more convenient for patients, potentially increasing adoption rates and driving royalty revenue for Halozyme. However, intensifying competition among GLP-1 drug producers could lead to pricing pressures or slower market penetration for specific partner products, indirectly impacting Halozyme's royalty streams. Additionally, regulatory hurdles or unforeseen side effects of GLP-1 drugs could reduce adoption, thereby affecting the market for Halozyme's delivery technologies in this segment.
3 Main Long-Term Bull Details
- Durable and Expanding Royalty Streams: Halozyme projects that 66% of the total projected royalty revenue from its current 10 ENHANZE launch products is still to come between 2026 and 2032, with more beyond that, acting as a "conducted revenue backlog". This strong base is further fueled by expanding indications for existing products and a pipeline of up to 13 new ENHANZE products expected to launch from 2029 onwards.
- New Growth Engines (Hypercon & Surf Bio): The acquisitions of Hypercon and Surf Bio provide new, long-duration intellectual property and are projected to generate significant new royalty income. Hypercon is expected to achieve approximately $1 billion in royalty revenues by the mid-2030s, with the first two product launches projected in 2030-2031. These technologies broaden Halozyme's capabilities and expand collaboration opportunities into new modalities and target product profiles.
- Strategic Partnerships and Pipeline Expansion: Halozyme continues to secure new collaboration and licensing agreements, having already signed three new deals in 2026, including with GSK for ADCs and Vertex and Oruka for Hypercon. The company also has a robust pipeline with 6 new ENHANZE targets expected to initiate Phase I testing in 2026, and opportunities for partners to nominate additional targets under existing agreements, ensuring a continuous stream of future launches and royalty revenue.
3 Main Long-Term Bear Details
- Patent Expirations and Royalty Erosion: While Halozyme emphasizes co-formulation patents extending royalty terms, the base composition of matter patents for ENHANZE are set to expire in 2029 in the U.S. and Europe. This could lead to increased competition from generic/biosimilar hyaluronidase products or pressure on royalty rates, potentially impacting revenue streams in the long term.
- Reliance on Partner Success and Concentration Risk: Halozyme's revenue is heavily dependent on the commercial success and continued development of its partners' ENHANZE-enabled products. Any clinical trial failures, regulatory setbacks, or underperformance of these products, particularly those from major partners like Johnson & Johnson (DARZALEX) or Roche (PHESGO, OCREVUS), could significantly impact Halozyme's royalty income.
- Integration and Commercialization Risks for New Technologies: The successful integration and commercialization of newly acquired technologies like Hypercon and Surf Bio carry inherent risks. These technologies are earlier stage, with first Hypercon approvals projected for 2030-2031, meaning significant revenue contributions are still years away and subject to clinical and regulatory success, as well as the ability to scale manufacturing.
- Competitors And Differentiation
- Halozyme's primary differentiation lies in its proprietary ENHANZE technology, which is considered the "gold standard" for subcutaneous drug delivery, particularly with monoclonal antibodies. The technology has a significant safety database, having been used to treat over 1.3 million patients. The company emphasizes its expertise in rapidly advancing partners into clinical development. While other companies may develop hyaluronidase technologies, Halozyme notes that partners typically approach them first for exclusive licenses due to their leadership position and established track record. Halozyme is also involved in intellectual property litigation against Merck and Alteogen, defending its patents. The acquisitions of Hypercon and Surf Bio further differentiate Halozyme by offering next-generation delivery solutions beyond ENHANZE, aiming to be a "one-stop shop" for biopharma.
- Recent Performance & What The Market'S Focused On
- Halozyme started 2026 with strong momentum, reporting a 42% year-over-year increase in total revenue to $377 million and a 43% increase in royalty revenue to $241 million for Q1 2026. This performance was driven by the continued adoption of ENHANZE-enabled products like DARZALEX subcutaneous, VYVGART Hytrulo, and PHESGO. The company reaffirmed its full-year 2026 financial guidance, projecting ENHANZE royalties to exceed $1 billion for the first time, representing 30-35% growth over 2025. The market is focused on the continued strong performance of its commercial ENHANZE portfolio, the progress of its Hypercon and Surf Bio technologies towards clinical development, the signing of new collaboration and licensing agreements (having already met its 2026 goal of three new deals), and the company's capital allocation strategy, including a new $1 billion share buyback authorization. Investors are also closely watching the long-term revenue durability post-2029, particularly the contribution from the pipeline of new ENHANZE and Hypercon launches.
- Revenue Segments And Estimated Mix
- Royalty Revenue — Mix: ~64% (Q1 2026); Source: Q1 2026 transcript: $240.7M out of $376.7M total revenue; Trend: Increased 43% year-over-year in Q1 2026; projected to exceed $1B for the first time in 2026, representing 30-35% gross over 2025.
- Product Sales — Mix: n/m; Source: Q1 2026 transcript: contributed to total revenue growth; Trend: Higher product sales to partners in Q1 2026 compared to prior year.
- Collaboration and Other Revenue — Mix: n/m; Source: Q1 2026 transcript: includes upfront milestones and potential for milestones from new deals; Trend: New deals in 2026 include upfront milestones and potential for future milestones.
- Product Brands
- ENHANZE
- Hylenex recombinant
- Hypercon
- Surf Bio
- Auto-injectors
- DARZALEX subcutaneous
- VYVGART Hytrulo
- PHESGO
- OCREVUS ZUNOVO
- OPDIVO Qvantig
- TECENTRIQ SC
- RYBREVANT FASPRO
Bull / Bear DetailsHalozyme Therapeutics maintains a strong bullish outlook as a leading biopharma technology platform company. Its ENHANZE technology continues to drive robust ro
Thesis
Halozyme Therapeutics maintains a strong bullish outlook as a leading biopharma technology platform company. Its ENHANZE technology continues to drive robust royalty revenue from blockbuster products, while strategic acquisitions of Hypercon and Surf Bio expand its subcutaneous drug delivery portfolio into new modalities like ADCs and nucleic acids. This positions Halozyme as a "one-stop shop" for partners, ensuring durable, high-margin royalty streams and significant pipeline expansion into the 2040s. (Updated: 2026-03-03)
Bull case
The continued exceptional performance and market penetration of ENHANZE-enabled blockbuster products like DARZALEX SC, PHESGO, and VYVGART Hytrulo are driving substantial royalty revenue growth. These products are expanding indications and achieving high conversion rates, with DARZALEX projected to exceed $18 billion in sales by 2028, securing Halozyme's near-term financial strength.
Halozyme has significantly broadened its drug delivery capabilities through the acquisitions of Hypercon and Surf Bio technologies, extending IP into the mid-2040s. These platforms, alongside ENHANZE and auto-injectors, position the company as a "one-stop shop" for biopharma, unlocking new collaboration opportunities and projected to generate approximately $1 billion in Hypercon royalties by the mid-2030s.
An expanding ENHANZE pipeline, with 6 new programs entering Phase I in 2026, and the emerging potential of ENHANZE with antibody drug conjugates (ADCs) and nucleic acids, represent significant long-term growth drivers. Preclinical data supports improved benefit-risk profiles for ADCs, attracting strong partner interest and accelerating royalty contributions from 2029.
Bear case
A significant portion of Halozyme's revenue is concentrated in a few key ENHANZE-enabled products and partnerships, particularly with Johnson & Johnson for DARZALEX. While an extension is expected, the expiry of the J&J agreement in 2032 poses a long-term risk. Additionally, ongoing intellectual property litigation, such as the case against Merck, introduces uncertainty and potential legal costs.
The successful integration and commercialization of newly acquired technologies like Hypercon and Surf Bio, along with the auto-injector platform, carry inherent risks. While promising, these technologies are earlier stage, with first Hypercon approvals projected for 2030-2031, meaning significant revenue contributions are still years away and subject to clinical and regulatory success.
Halozyme anticipates a sequential decrease in royalty and total revenue in Q1 2026 due to annual contractual rate resets and milestone weighting in the second half of the year. Furthermore, significant investments in new technologies like Hypercon and Surf Bio, reflected in acquired IPR&D expenses, can impact short-term profitability and diluted EPS, as seen in 2025.
Bull / Bear Case
- Bear Case
- A significant portion of Halozyme's current revenue is concentrated in a few key ENHANZE-enabled products and partnerships, notably with Johnson & Johnson for DARZALEX, whose agreement expires in 2032, posing a long-term risk. The successful integration and commercialization of newly acquired technologies like Hypercon and Surf Bio, along with the auto-injector platform, carry inherent risks as these are earlier-stage, with significant revenue contributions projected years away (Hypercon approvals in 2030-2031). Ongoing intellectual property litigation, such as the case against Merck, introduces uncertainty and potential legal costs that could impact profitability and market exclusivity. Furthermore, the company anticipates a sequential decrease in royalty and total revenue in Q1 2026 due to contractual rate resets and milestone weighting, and significant acquired IPR&D expenses have impacted short-term profitability and diluted EPS, as seen in 2025.
- Bull Case
- Halozyme Therapeutics is positioned for durable, high-margin royalty revenue and exceptional value creation well into the 2040s. This is driven by the continued strong performance and market penetration of its ENHANZE-enabled blockbuster products like DARZALEX SC, PHESGO, and VYVGART Hytrulo, with DARZALEX projected to exceed $18 billion in sales by 2028. The company has significantly expanded its drug delivery capabilities through the acquisitions of Hypercon and Surf Bio technologies, extending its intellectual property and positioning itself as a 'one-stop shop' for biopharma. An expanding ENHANZE pipeline, with 6 new programs entering Phase I in 2026, and the emerging potential of ENHANZE with antibody drug conjugates (ADCs) and nucleic acids, represent significant long-term growth drivers, with Hypercon alone projected to generate approximately $1 billion in royalties by the mid-2030s. The company reiterated strong 2026 financial guidance, including substantial royalty and EPS growth.
- More Compelling & Why
- Bull. Halozyme's forward EV/EBITDA of 9.4x is significantly below the broader Healthcare sector median of 16.64x, despite management guiding to nearly 100% EPS growth in 2026. The market appears to be under-appreciating the company's strong near-term earnings inflection and the long-term durability of its expanded drug delivery platforms. Failure to meet 2026 financial guidance, particularly royalty revenue and EPS growth targets, or a material adverse outcome in the ongoing intellectual property litigation, would flip my view.
Key Factors
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| Initiation of Phase I Clinical Studies for New ENHANZE and Hypercon Programs | Entry into Phase I signifies critical pipeline progression, laying the groundwork for future commercial products and accelerating royalty contributions from the development portfolio starting in 2029. | Number of new ENHANZE programs entering Phase I (guidance: 6 in 2026); number of new Hypercon programs entering Phase I (guidance: 2 in 2026). | Bullish: More than 6 ENHANZE programs or more than 2 Hypercon programs entering Phase I in 2026. Bearish: Fewer than 6 ENHANZE programs or fewer than 2 Hypercon programs entering Phase I in 2026. | Halozyme's quarterly earnings calls, company press releases, and clinicaltrials.gov for new study registrations. | Clinicaltrials.gov: Search for "Halozyme" or "rHuPH20" and "Phase 1" or "Hypercon" and "Phase 1" for new study registrations. | Citeline (TrialTrove): Clinical trial database for new Phase I study initiations and updates. |
| Achievement of De-leveraging Target and Strategic M&A Announcements | Achieving the de-leveraging target demonstrates financial discipline and strengthens the balance sheet, while strategic M&A can expand the technology portfolio and drive near-term and long-term revenue growth. | Halozyme's reported net debt to EBITDA ratio (target below 1x by end of 2026); announcement of any new acquisitions (drug delivery technologies or revenue/margin assets). | Bullish: Reporting a net debt to EBITDA ratio below 1x by Q4 2026; announcement of an acquisition that significantly enhances the portfolio or adds substantial revenue. Bearish: Indications that the net debt to EBITDA target will not be met; no significant strategic acquisitions announced in 2026. | Halozyme's quarterly earnings reports and calls (for financial updates and M&A strategy), company press releases, SEC filings (Form 8-K for acquisitions). | Financial news outlets (e.g., Bloomberg, Reuters, Wall Street Journal) for M&A rumors or announcements. | S&P Capital IQ: Company financial statements and debt metrics; Mergermarket: M&A deal intelligence. |
| Progress in ENHANZE Application to Antibody Drug Conjugates (ADCs) | This represents a significant new market opportunity, potentially expanding ENHANZE's utility beyond monoclonal antibodies and unlocking high-value collaborations and substantial future royalty streams. | Public announcement of a new ENHANZE collaboration specifically for an ADC; initiation of a Phase I clinical study for an ENHANZE-enabled ADC. | Bullish: Signing of the first ENHANZE collaboration agreement for an ADC; public announcement of an ADC entering clinical development with ENHANZE. Bearish: No announced progress or partnerships related to ADCs with ENHANZE by year-end 2026. | Halozyme's press releases, quarterly earnings calls, and scientific conference presentations by Halozyme or potential partners. | Industry news outlets focused on oncology and ADCs (e.g., ADC Review, Cancer Research Institute news). | BioCentury: Partnership tracking for emerging drug modalities; EvaluatePharma: Pipeline analysis for ADCs in development. |
| Announcement of New ENHANZE, Hypercon, or Surf Bio Collaboration and Licensing Agreements | These agreements validate Halozyme's drug delivery platforms and are crucial for expanding its future royalty revenue streams and market reach across various therapeutic areas. | Number of new ENHANZE collaborations (guidance: 1 to 3 in 2026); number of new Hypercon collaborations (guidance: 1 to 2 in 2026). | Bullish: Announcing 3 or more new ENHANZE agreements, or 2 or more new Hypercon agreements, or any new Surf Bio agreement in 2026. Bearish: Announcing fewer than 1 new ENHANZE agreement or 1 new Hypercon agreement by year-end 2026. | Halozyme's official press releases, SEC filings (Form 8-K for material agreements), and quarterly earnings call transcripts. | Biotechnology industry news websites (e.g., Fierce Biotech, Endpoints News) for partnership announcements. | EvaluatePharma: Licensing deal database for new biopharma collaborations. |
| Reported Conversion Rates and Sales Performance of DARZALEX SC, PHESGO, and OPDIVO Qvantig | Strong conversion from IV to subcutaneous formulations and robust sales growth for these blockbuster products directly drive Halozyme's royalty revenue, which is its principal growth driver. | PHESGO: Roche's reported global conversion rate from IV Perjeta (target 60%). OPDIVO Qvantig: BMS's reported conversion rate (target 30-40% by 2028). DARZALEX SC: Johnson & Johnson's reported operational sales growth (projected to exceed $18 billion in 2028). | Bullish: PHESGO global conversion rate exceeding 60%; OPDIVO Qvantig conversion rate showing strong sequential progress towards 30-40%; DARZALEX operational sales growth exceeding 2025's 22%. Bearish: Stagnation or decline in conversion rates for PHESGO or OPDIVO Qvantig; significant slowdown in DARZALEX operational sales growth. | Quarterly earnings calls and press releases from partner companies (Johnson & Johnson, Roche, Bristol-Myers Squibb), and Halozyme's quarterly earnings calls. | Partner company investor relations websites for earnings transcripts and presentations. | IQVIA: Prescription data and market share for specific ENHANZE-enabled drugs. |
Key Reported Metrics, Reratings Triggers & ResultsAdjusted EBITDA provides a clear view of Halozyme's operational profitability, excluding non-cash and non-recurring items, which is crucial for assessing its fi
| Key reported metrics | Rerating thresholds | ||||
|---|---|---|---|---|---|
| Metric | Last period | Why it matters | What's needed for rerating | Rerating context | Earnings date |
| Adjusted EBITDA | -88.81% | Adjusted EBITDA provides a clear view of Halozyme's operational profitability, excluding non-cash and non-recurring items, which is crucial for assessing its financial strength and ability to fund future growth. The significant decline in Q4 2025 warrants close attention. | Halozyme Therapeutics' Adjusted EBITDA margin needs to reach or exceed 70% for the full year 2026. This would significantly surpass the current value of 42% and demonstrate an accelerated trajectory towards the company's stated target of approximately 70% Adjusted EBITDA margin by 2028. | Achieving an Adjusted EBITDA margin of 70% or higher for 2026 is crucial as it directly reflects Halozyme's robust operational profitability and the efficiency of its high-margin royalty-driven business model. This would signal accelerated execution on its strategy, reinforcing investor confidence in the durability of its revenue streams and its ability to generate substantial cash flow for future growth and shareholder returns, thereby justifying a higher valuation and positive rerating. | |
| Total Revenue | 52% | Total revenue indicates the overall financial health and growth trajectory of Halozyme, driven by its ENHANZE technology and new acquisitions. Investors monitor this for sustained expansion and market penetration. | For the stock to rerate higher, Halozyme Therapeutics' Total Revenue for the full year 2026 needs to exceed the high end of its reiterated guidance of $1.81 billion. For the upcoming Q2 2026 earnings, reporting Total Revenue significantly above the implied quarterly run rate needed to achieve the high end of full-year guidance (approximately $478 million for Q2, Q3, and Q4, given Q1 was $377 million and the high end of full-year guidance is $1.81 billion), coupled with an upward revision to the full-year outlook, would drive a higher rerating. | Exceeding the high end of guidance or significantly beating expectations demonstrates stronger-than-anticipated adoption of ENHANZE-enabled products and successful integration/commercialization of new technologies like Hypercon and Surf Bio. This validates the long-term royalty growth thesis, strengthens the company's competitive position as a 'one-stop shop' for drug delivery, and signals durable, high-margin revenue streams, leading to increased investor confidence and a higher valuation multiple. | |
| Royalty Revenue | 51% | Royalty revenue is the principal growth driver for Halozyme, reflecting the successful adoption and conversion of ENHANZE-enabled products. Its durability into the 2040s is key to long-term value. | Halozyme Therapeutics needs to reaffirm or raise its full-year 2026 royalty revenue guidance of $1.13 billion to $1.17 billion, which represents 30-35% growth over 2025. Additionally, demonstrating strong sequential growth in royalty revenue in Q2 2026, following the Q1 sequential decrease, and providing positive updates on new Hypercon and ADC collaborations would be crucial for a higher rerating. | Hitting these royalty revenue targets validates the strength and durability of Halozyme's ENHANZE platform and its expanding portfolio with Hypercon and Surf Bio. This confirms the long-term investment thesis of high-margin, compounding royalty streams, reducing concerns about patent expiry and driving a positive rerating through improved valuation and market confidence. | |
Key QuestionsWill Halozyme execute on its reaffirmed full-year 2026 financial guidance, particularly regarding the projected ENHANZE royalty growth exceeding $1 billion and
Will Halozyme meet its Q1 2026 revenue guidance, particularly the projected sequential decrease in royalty and total revenue, and reaffirm its full-year 2026 financial outlook?
- Question 2
How much progress will Halozyme demonstrate in securing new ENHANZE and Hypercon licensing agreements and advancing new programs into Phase I clinical studies, especially regarding the emerging ADC opportunity?
- Question 3
Will there be any significant developments or clarity regarding the ongoing intellectual property litigation against Merck and Alteogen, particularly the scheduling and initial proceedings of the District Court case?
Earnings Transcript Summary
· 2026Q1 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 1. **Maximizing value from organic investments and supporting partner success:** Management is investing in ENHANZE, Hypercon, and Surf Bio to support partner success and maximize the value of their organic investments, including finalizing clinical supply manufacturing for Hypercon and investing in manufacturing capacity to offer end-to-end services to Hypercon partners. 2. **Returning value to shareholders and disciplined capital allocation:** The company announced a new $1 billion share buyback authorization, with an expectation of buying back at least $400 million in 2026, and plans to deleverage further by retiring 2027 and 2028 notes. They also continue to evaluate drug delivery M&A opportunities. 3. **Driving long-term durable revenue growth beyond 2029:** Management is focused on four key drivers for revenue in the 2029+ period: continued performance of the 10 current ENHANZE launch products (with 66% of projected royalties still to come), up to 13 new ENHANZE launches from the current pipeline, two Hypercon product launches in 2030-2031, and additional launches from new nominations and collaboration agreements for ENHANZE, Hypercon, and Surf Bio. | The call conveyed a highly confident and positive tone, emphasizing Halozyme's strong start to 2026 with exceptional momentum. The key takeaway was the reaffirmation of robust financial guidance for 2026 and 2026-2028, driven by the continued strong performance of existing ENHANZE products and the significant long-term growth potential from new ENHANZE, Hypercon, and Surf Bio launches extending beyond 2029. Management highlighted disciplined capital allocation, including a new $1 billion share buyback program, and expressed strong conviction in bending the revenue curve favorably in the 2029+ period, countering skeptics. | Total revenue increased 52% year-over-year. Royalty revenue increased 51% year-over-year. Product sales increased 54.5% year-over-year. Revenues under collaborative agreements increased 47.5% year-over-year. DARZALEX subcutaneous royalty revenue increased 29% year-over-year (Full Year 2025). PHESGO royalty revenue increased 51% year-over-year (Full Year 2025). VYVGART Hytrulo royalty revenue increased 444% year-over-year (Full Year 2025). *Note: Q4 2025 specific year-over-year growth rates for DARZALEX SC, PHESGO, and VYVGART Hytrulo royalty revenues were not explicitly provided in the search results; full-year 2025 growth rates are used instead.* | 1. **Future ENHANZE product profile post-2029 and Hypercon deal origins:** An analyst inquired about the biggest products in the 2029+ ENHANZE portfolio and their peak timing, and how many Hypercon discussions were ongoing before the acquisition versus new ones. *Management Response:* Helen Torley highlighted that 66% of revenue from current launch products is still to come between 2026 and 2032, with multiple large contributors like OCREVUS, RYBREVANT, VYVGART, and DARZALEX. For Hypercon, one discussion was ongoing pre-acquisition, and one was new, with continued broadening interest and additional targets in development. 2. **Hypercon Phase I timing and manufacturing readiness:** An analyst inquired about what remains to be done on Halozyme's side to get the two Hypercon Phase I clinical starts ready for the first half of 2027, and if the timing for revealing the targets remains the same. *Management Response:* Helen Torley stated that they are working on clinical manufacturing and investing in capacity to offer end-to-end services. Partners will likely reveal targets closer to the Phase I start when they post on clinicaltrials.gov. 3. **Scalability of Hypercon technology and manufacturing scale-up for Hypercon vs. Surf Bio:** An analyst questioned the scalability of Hypercon, given Elektrofi didn't enter clinics with it, and how Halozyme's expertise helps. Another question compared manufacturing scale-up for Hypercon and Surf Bio. *Management Response:* Helen Torley expressed confidence in Hypercon's progress, noting collaboration with CDMOs like Thermo Fisher Patheon for clinical batches and plans to invest in commercial manufacturing capacity. She explained that Surf Bio is 18-24 months earlier in development, relies on spray drying (a common manufacturing type), while Hypercon is a novel dehydration process for microparticles, both requiring different but advancing manufacturing efforts. | Royalty revenues increased 43% year-over-year. Total revenue increased 42% year-over-year. DARZALEX subcutaneous royalty revenue increased 26% year-over-year. VYVGART Hytrulo royalty revenue increased 119% year-over-year. PHESGO royalty revenue increased 25% year-over-year. |
· 2025Q4 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 1. **Expanding drug delivery technology portfolio**: Management highlighted the acquisition of Elektrofi's Hypercon technology and Surf Bio's hyperconcentration technology, expanding their subcutaneous drug delivery capabilities from 2 to 4 technologies with long-duration IP into the mid-2040s. This aims to position Halozyme as a comprehensive solution provider for the biopharma industry. 2. **Driving long-term durable and profitable royalty revenue**: This focus is evident through the continued strong performance of existing ENHANZE-enabled blockbuster products (DARZALEX SC, PHESGO, VYVGART Hytrulo), the early growth of recently launched ENHANZE products (OCREVUS, OPDIVO, RYBREVANT, TECENTRIQ), and the expansion of the ENHANZE pipeline with projected new programs and licensing agreements. They also anticipate approximately $1 billion in Hypercon royalty revenue within five years of its first launches in the mid-2030s. 3. **Strategic M&A and disciplined capital allocation**: Management emphasized deploying strong cash flow towards strategic acquisitions that further strengthen their drug delivery portfolio and add assets with strong revenue and margin opportunities. They also plan to maintain financial discipline, expecting to de-lever to below 1x net debt to EBITDA by the end of 2026. | The call conveyed a highly positive, confident, and energized tone. The overarching takeaway was Halozyme's strong financial and operational performance in 2025, marked by record revenue and robust royalty growth, primarily driven by its ENHANZE technology. Management highlighted significant strategic expansion through the acquisition of Hypercon and Surf Bio technologies, solidifying Halozyme's position as a leading provider of subcutaneous drug delivery solutions with a clear long-term growth strategy extending into the 2040s. The emerging opportunity to apply ENHANZE to antibody-drug conjugates (ADCs) and nucleic acids was presented as an exciting new growth driver. The company also reiterated strong financial guidance for 2026, underscoring its confidence in future growth and value creation. | In the third quarter of 2025, Halozyme reported total revenue growth of 22% year-over-year to $354.3 million. Royalty revenue in Q3 2025 increased 52% year-over-year to $236 million. Product sales in Q3 2025 increased 8.7% year-over-year to $94.2 million. Revenues under collaborative agreements decreased 50.4% year-over-year to $24 million in Q3 2025. Specific year-over-year growth rates for DARZALEX subcutaneous, PHESGO, and VYVGART Hytrulo royalty revenues for Q3 2025 were not explicitly detailed in the search results. | 1. **Mechanics and future of DARZALEX collaboration with J&J**: An analyst inquired about the potential to expand the deal with J&J on DARZALEX (ENHANZE or Hypercon) and the mechanics after the ENHANZE collaboration expiry in 2032. *Management Response*: Helen Torley stated that they expect to enter discussions with Johnson & Johnson closer to 2032 to extend their ENHANZE agreement and API supply, emphasizing J&J's likely desire to continue working with Halozyme due to reliability and safety track record. Her comments specifically referred to ENHANZE. 2. **ADC strategy: Regulatory pathway and treatment paradigms**: An analyst asked about the regulatory path for improving approved ADCs with ENHANZE versus new molecules, and whether subcutaneous ADCs would truly free up infusion center time or still require IV center visits. *Management Response*: Chris Wahl explained that for converting approved ADCs from IV to SC, the regulatory path would likely involve PK non-inferiority studies, similar to monoclonal antibodies. For new products seeking additional efficacy and safety benefits, full phase trials would be required. He noted that while ADCs in combination therapy can reduce infusion center time, the increasing use of ADCs in first-line therapy and in combination with other subcutaneous drugs (many enabled by ENHANZE) could lead to IV-free regimens and at-home administration. 3. **Hypercon product progress and updates**: An analyst asked for an update on the progress of Hypercon products towards clinical testing, what remains to be done before Phase I, and what updates to anticipate regarding the products and development strategy. *Management Response*: Helen Torley confirmed that 2 Hypercon programs, involving established blockbuster mechanisms of action, are on track to enter Phase I clinical testing by the end of 2026. Remaining steps include completing clinical scale-up batches and filing IND packages. She noted that updates would be partner confidential but likely posted on clinicaltrials.gov, and the development pathway would be familiar, involving Phase I for dose identification and Phase III for non-inferiority. | Total revenue for the full year 2025 grew 38% to $1.4 billion. Royalty revenue for the full year 2025 increased 52% to $867.8 million. DARZALEX subcutaneous royalty revenue grew 29% year-over-year for the full year 2025. PHESGO royalty revenue grew 51% year-over-year for the full year 2025. VYVGART and VYVGART Hytrulo royalty revenue grew 444% year-over-year for the full year 2025. Total revenue for the fourth quarter of 2025 increased 52% to $451.8 million. Royalty revenue for the fourth quarter of 2025 increased 51% to $258 million. Product sales also contributed to the year-over-year total revenue growth for the full year 2025, though a specific percentage was not provided. |
Transcript Tidbits
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| Halozyme's ENHANZE-enabled products are expanding their eligible market through new indications and approvals. DARZALEX FASPRO received its fifth frontline approval and was also approved for earlier second-line treatment in relapsed or refractory multiple myeloma. VYVGART and VYVGART Hytrulo received FDA approval as the first and only treatment for all serotypes of adult patients with generalized myasthenia gravis, which is expected to double the potential addressable patient base. Positive Phase III data for ocular myasthenia gravis could further double this opportunity. OCREVUS ZUNOVO is expanding access by enabling treatment in community practices, with approximately 60% of U.S. starts now from these settings, and Roche anticipates an additional CHF 2 billion in sales for OCREVUS by 2029 due to the subcutaneous formulation. A new collaboration with GSK for oncology targets, including antibody drug conjugates (ADCs), extends ENHANZE into one of the fastest-growing and largest TAM areas of oncology. A Hypercon collaboration with Oruka targets the $20 billion to $25 billion global moderate to severe psoriasis market. Discussions are also ongoing for nucleic acid applications of ENHANZE. | Halozyme views its ENHANZE technology as the 'gold standard,' with over 1.3 million patients treated, and partners consistently choose Halozyme first due to its acknowledged expertise in rapid clinical development. The company's unique co-formulation patent business model is critical for extending royalty terms beyond the base composition of matter patent expirations (2029 in the U.S. and Europe), potentially for up to 20 years from filing, often while maintaining original royalty rates. Halozyme cannot comment on specific competitive activities like Sanofi's complementary hyaluronidase due to lack of full awareness and existing exclusive licenses with partners. | A significant secular trend in the broader industry is the shift towards subcutaneous (SC) drug delivery, with SC delivery at home becoming the target product profile for many disease conditions. There is a growing demand for extended dosing and patient self-administration via simple, off-the-shelf auto-injectors, particularly in therapeutic areas like inflammation, immunology, nephrology, and cardiovascular diseases, where patient freedom and at-home treatment are highly valued. Antibody drug conjugates (ADCs) are identified as one of the fastest-growing and largest total addressable market (TAM) areas in oncology. | Halozyme reaffirms its full-year 2026 and 2026-2028 financial guidance, projecting ENHANZE royalties to exceed $1 billion for the first time in 2026 (30-35% growth over 2025) and adjusted EBITDA margin to reach approximately 70% by 2028. Capital allocation priorities include maximizing organic investments (ENHANZE, Hypercon, Surf Bio), a new $1 billion share buyback authorization (at least $400 million in 2026, targeting 3% annual yield), deleveraging by retiring 2027 and 2028 notes, and evaluating drug delivery M&A opportunities (though unlikely to transact in 2026). Post-2029 revenue will be driven by the continued performance of 10 current ENHANZE products (66% of projected royalties still to come between 2026-2032), up to 13 new ENHANZE launches (2029+), 2 Hypercon launches (2030-2031), and additional launches from new nominations and collaboration agreements. Two Hypercon products are projected to start Phase I clinical testing in the first half of 2027, with launch timing remaining 2030-2031, and Hypercon is expected to achieve approximately $1 billion in royalty revenues by the mid-2030s. Halozyme has already met its 2026 goal of signing 3 new collaboration and licensing agreements and anticipates additional agreements this year. The company projects net leverage to be approximately 1.2x by the end of 2026. Surf Bio is 18-24 months behind Hypercon in development, with nucleic acid deals anticipated in the coming months/quarters. | Pharma/Therapeutics: | Patient-centric care and the shift towards at-home administration of therapeutics via subcutaneous injections and auto-injectors. The increasing importance of advanced drug delivery technologies to optimize product profiles, reduce treatment burden, and expand market access for a wide range of therapeutic areas, including oncology and immunology. | We started 2026 with exceptional momentum. ENHANZE royalties to exceed $1 billion for the first time. The majority of the royalty revenue from these 10 products is still to come. We intend to make Hypercon the next in hands-like success story. We are delighted to have signed 3 new collaboration and licensing agreements in 2026, already meeting our goal for 2026 to execute 3 new deals this year. And we're not stopping here. By owning a share of Halozyme, you're owning a broad swath of the biopharma industry. | It is unlikely that we will identify a drug delivery opportunity that meet the criteria to transact on in 2026. And we do not foresee M&A outside of drug delivery. The base composition of matter patents will expire in 2029 in the U.S. and in Europe. |
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| Halozyme expanded its portfolio from 2 to 4 subcutaneous drug delivery technologies with the acquisitions of Elektrofi's Hypercon and Surf Bio's hyperconcentration technologies, both with long-duration IP into the mid-2040s, significantly broadening collaboration opportunities across various targets, modalities, and therapeutic areas. DARZALEX FASPRO received approval in the U.S. for smoldering multiple myeloma, and Johnson & Johnson announced another approval for newly diagnosed multiple myeloma patients, marking the 12th indication overall. RYBREVANT subcutaneous with ENHANZE achieved regulatory approvals in the U.S., Japan, and China. Roche nominated a new ENHANZE target, and argenx expanded its ARGX-121 Phase I study with ENHANZE, indicating partners moving earlier-stage assets into subcutaneous development. Halozyme signed 3 new ENHANZE collaboration and licensing agreements, extending its reach beyond oncology into obesity and inflammatory bowel disease. OCREVUS ZUNOVO is expanding the addressable market by enabling use in community practices and overcoming intravenous infusion capacity constraints. VYVGART Hytrulo is exploring expanded and new indications for long-term growth. The company recognizes ENHANZE's potential to improve the clinical profile and convenience of antibody drug conjugates and nucleic acids. Hypercon is designed to meet the growing demand for lower volume auto-injector-ready at-home or in HCP office therapies, and by 2028, the combined commercial and development portfolio with ENHANZE, Hypercon, and Surf Bio is expected to nearly double from 19 to 36 products. | Halozyme expects to enter discussions with Johnson & Johnson to extend their ENHANZE agreement and API supply beyond 2032, indicating J&J's reliance on Halozyme's API and its strong reliability and safety track record. ENHANZE is recognized as the 'gold standard' for use with monoclonal antibodies, reflecting a strong competitive position. The company is involved in an IPR filed against Alteogen and a District Court litigation against Merck, alleging infringement of multiple Halozyme patents, highlighting efforts to defend its intellectual property against competitive challenges. | There is a significant industry push towards moving treatments to simple, short, small injections that can be administered in a doctor's office or at home, particularly for conditions like autoimmune diseases, neurology, and nephrology. This shift towards subcutaneous administration is expected to lead to a significant reduction in patients needing to visit infusion centers. The company also highlights the emerging and rapidly growing classes of antibody drug conjugates and nucleic acids as areas where drug delivery technologies like ENHANZE can improve clinical profiles and convenience. | Halozyme aims to be the 'one-stop shop' for the biopharma industry for subcutaneous drug delivery. DARZALEX sales are projected to exceed $18 billion in 2028, and PHESGO is expected to reach $3.6 billion in 2028. The combined IV and subcutaneous opportunity for OCREVUS, OPDIVO, RYBREVANT, and TECENTRIQ is estimated at approximately $30 billion in 2028. BMS targets 30% to 40% conversion for OPDIVO Qvantig by its loss of exclusivity in 2028. Halozyme anticipates royalty revenue durability and exceptional value creation well into the 2040s. In 2026, 6 new ENHANZE programs and 2 new Hypercon programs are projected to enter Phase I, expanding the development portfolio to 15 products, with accelerated royalty contributions from the pipeline expected to begin in 2029. The company expects 1 to 3 new ENHANZE agreements and 1 to 2 new Hypercon agreements in 2026. Hypercon's first approvals are projected in 2030-2031, with approximately $1 billion in Hypercon royalty revenue expected within 5 years of these launches in the mid-2030s. Surf Bio's clinical readiness is targeted for late 2027 or 2028. By 2028, the combined commercial and development portfolio is expected to nearly double to 36 products. Halozyme plans to continue strategic M&A to expand its drug delivery portfolio and acquire assets for near-term and long-term growth. For 2026, the company reiterates total revenue guidance of $1.71 billion to $1.81 billion, and royalty revenue guidance of $1.13 billion to $1.17 billion. Adjusted EBITDA is projected between $1.125 billion and $1.205 billion, with non-GAAP diluted EPS of $7.75 to $8.25. First-quarter royalty revenues are expected to decrease sequentially by 5% to 10% from Q4 2025 due to contractual rate resets, with sequential growth thereafter, and total revenue to decrease sequentially in Q1 2026 due to milestone weighting in the second half of the year. | Pharma/Therapeutics: | A broader theme emerging is the strong industry push towards patient-centric care, emphasizing the shift of drug administration to simpler, shorter, and smaller injections that can be done at home or in a doctor's office, giving patients more control over their treatment. This trend is leading to a significant reduction in the need for patients to visit infusion centers as more drugs become available in subcutaneous formulations. The increasing importance of advanced drug delivery technologies like ENHANZE, Hypercon, and Surf Bio in enabling this shift and enhancing the clinical profile of emerging drug classes is also a prominent theme. | 2025 was one of the most significant and value-creating years in Halozyme's history. Halozyme as the one-stop shop for the biopharma industry for subcutaneous drug delivery. DARZALEX is expected to continue this strong trajectory with sales projected to exceed $18 billion in 2028. We have multiple levers and drivers of revenue that will position Halozyme for royalty revenue durability and exceptional value creation well into the 2040s. Interest for ENHANZE has never been higher from pharma and biotech. We are projecting that... approximately $1 billion in Hypercon royalty revenue within 5 years of the first launches. By 2028, we expect our combined commercial and development portfolio... to nearly double from 19 products today to 36. We are pleased to reiterate our 2026 financial guidance. | Net income for the full year was $316.9 million, which includes $285 million of acquired IPR&D expense related to the Surf Bio acquisition. Both 2025 GAAP and non-GAAP diluted EPS included the unfavorable impact of approximately $2.30 per share from the Surf Bio acquired IPR&D expense. We expect first quarter royalty revenues to be less than the fourth quarter of 2025 by approximately 5% to 10% due to annual contractual rate resets. We project total revenue to decrease sequentially from the fourth quarter of 2025 to the first quarter of 2026 as no milestones are planned in the first quarter. |
Notes
| Date | Comment | Comment Type | Comment Sentiment | Link | Price Reaction |
|---|---|---|---|---|---|
| 2026-02-17 | Halozyme reported strong 2025 results and robust 2026 guidance, driven by ENHANZE product growth and new technologies like Hypercon and ADC opportunities. Despite this positive outlook and strategic expansions, the market reacted negatively, with the stock significantly underperforming SPY by 11.80% post-earnings. This suggests investor disappointment, possibly due to high expectations, the IPR&D charge, or the projected Q1 2026 revenue cadence. | Other | Bearish | -11.80% (vs SPY: -12.76%) |
Upcoming Events
No data for this section.